Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Capivasertib fits the bill for HR+, HER2– ABC
Capivasertib, when added to fulvestrant, prolonged progression-free survival (PFS) by 4.1 months in an analysis of Chinese patients with hormone receptor–positive (HR+), HER2-negative (HER2– ABC) advanced breast cancer (ABC) whose disease had progressed on aromatase inhibitor, with or without a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor in the phase III CAPItello-291 trial.
Capivasertib fits the bill for HR+, HER2– ABC
22 Jan 2024Vaccines protect liver disease patients against severe COVID-19
Patients with liver disease develop antibodies and T-cell responses following three shots of COVID-19 vaccines, while those who have been infected with SARS-CoV-2 develop mild symptoms only, reports a recent study.
Vaccines protect liver disease patients against severe COVID-19
20 Jan 2024PAGED-B score predicts HCC risk in patients entering into CHB
A novel risk score, PAGED-B, may be used to predict hepatocellular carcinoma (HCC) development at the time of transition into hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB), suggests a study.